United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
Business Wire•04/11/2026•06:30 ET
0
Key Highlights
- ➤Q3 revenue $832.5 million, up 4% year-over-year
- ➤Net income $258.6 million, down 24% year-over-year
- ➤Tyvaso DPI revenue $378.5 million, up 13%
- ➤Research and development expense surged 119% to $279.2 million
- ➤October board authorized a new $2.0 billion share repurchase program
Expert Statements
Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics
“United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve”
Michael Benkowitz, President and Chief Operating Officer of United Therapeutics
“Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization.”
Michael Benkowitz, President and Chief Operating Officer of United Therapeutics
“Our strategies are delivering, securing an increasingly strong position to leverage our commercial operations. With a durable and robust foundation combined with significant new opportunities across cardiopulmonary and respiratory medicine rapidly approaching, we believe we have the strongest growth outlook in our history.”
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025.
Get started
Create a free account to read the full story.